ADCT

3.39

0.29% -0.010

Dopo l'orario di chiusura: 3.39

Adc Therapeutics Sa (ADCT)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Forum Previsione

Precedente Chiudi:

$3.40

Aprire:

$3.41

Volume 24 ore:

486.24K

Relative Volume:

0.49

Capitalizzazione di mercato:

$431.18M

Reddito:

$79.18M

Utile/perdita netta:

$-136.99M

Rapporto P/E:

-3.2142

EPS:

-1.0547

Flusso di cassa netto:

$-120.11M

1 W Prestazione:

+4.31%

1M Prestazione:

-17.11%

6M Prestazione:

-15.67%

1 anno Prestazione:

+52.02%

Intervallo 1D:

$3.355

$3.45

Intervallo di 1 settimana:

$3.10

$3.45

Portata 52W:

$2.045

$4.98

Adc Therapeutics Sa Stock (ADCT) Company Profile

Nome

Adc Therapeutics Sa

Settore

Healthcare (1108)

Industria

Biotechnology (618)

Telefono

41 21 653 02 00

Indirizzo

BIOPOLE, EPALINGES

Dipendente

193

Cinguettio

Prossima data di guadagno

2026-05-04

Ultimi documenti SEC

ADCT's Discussions on Twitter

Compare ADCT vs VRTX, REGN, ARGX, ALNY, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ADCT Adc Therapeutics Sa	3.39	432.45M	79.18M	-136.99M	-120.11M	-1.0547
VRTX Vertex Pharmaceuticals Inc	434.52	110.03B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	638.88	67.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	806.46	50.76B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	297.45	40.12B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	151.56	32.68B	742.00K	-1.37B	-1.07B	-7.0731

Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-11-08	Iniziato	Stephens	Overweight
2024-05-30	Iniziato	Cantor Fitzgerald	Overweight
2024-03-28	Iniziato	Guggenheim	Buy
2023-08-10	Aggiornamento	JP Morgan	Underweight → Neutral
2023-04-24	Downgrade	BofA Securities	Neutral → Underperform
2022-12-06	Iniziato	CapitalOne	Overweight
2022-11-09	Downgrade	BofA Securities	Buy → Neutral
2022-09-21	Iniziato	JP Morgan	Overweight
2022-09-09	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2021-11-09	Iniziato	Wolfe Research	Outperform
2021-08-17	Ripresa	Jefferies	Buy
2021-08-09	Iniziato	RBC Capital Mkts	Outperform
2021-06-15	Iniziato	Cantor Fitzgerald	Overweight
2020-12-03	Iniziato	Stifel	Hold
2020-10-29	Iniziato	H.C. Wainwright	Buy
2020-06-09	Iniziato	BofA/Merrill	Buy
2020-06-09	Iniziato	Cowen	Outperform

Mostra tutto

Adc Therapeutics Sa Borsa (ADCT) Ultime notizie

May 17, 2026

ADC Therapeutics targets $600M-$1B US peak ZYNLONTA revenue as LOTIS-5 top-line data is expected by end of June - MSN

May 17, 2026

ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update - Quantisnow

May 10, 2026

May 08, 2026

Are medical stocks lagging ADC Therapeutics (ADCT) this year? - MSN

May 08, 2026

HC Wainwright & Co. Maintains ADC Therapeutics (ADCT) Buy Recommendation - MSN

May 08, 2026

ADC Therapeutics (ADCT) Earnings Date and Reports 2026 - MarketBeat

May 08, 2026

May 07, 2026

Q2 EPS Estimate for ADC Therapeutics Decreased by Analyst - MarketBeat

May 07, 2026

Analysts Have Made A Financial Statement On ADC Therapeutics SA's (NYSE:ADCT) First-Quarter Report - simplywall.st

May 07, 2026

May 05, 2026

ADC Therapeutics Q1 2026 Earnings: Revenue Growth and ZYNLONTA MilestonesNews and Statistics - IndexBox

May 05, 2026

ADC Therapeutics: 'Strong Buy' With 2 Shots On Goal For ZYNLONTA In R/R DLBCL (ADCT) - Seeking Alpha

May 05, 2026

ADC Therapeutics SA 2026 Q1ResultsEarnings Call Presentation (NYSE:ADCT) 2026-05-05 - Seeking Alpha

May 05, 2026

ADC Therapeutics (NYSE:ADCT) Receives "Outperform" Rating from Royal Bank Of Canada - MarketBeat

May 05, 2026

ADC Therapeutics (NYSE:ADCT) Receives "Buy" Rating from HC Wainwright - MarketBeat

May 05, 2026

ADC Therapeutics S.A. (NYSE:ADCT) Q1 2026 Earnings Call Transcript - Insider Monkey

May 05, 2026

ADC Therapeutics SA Q1 2026 Financial Results: Revenue, Losses, and Forward-Looking Statements - Minichart

May 05, 2026

ADC Therapeutics to Host First Quarter 2026 Financial Results Co - GuruFocus

May 05, 2026